OBJECTIVE: To investigate the association between a low ankle-brachial index (ABI) and several grades of cognitive disorders: cognitive impairment, dementia and Alzheimer's disease (AD), in the general population. METHODS: We performed a systematic review of the literature, including all prospective, longitudinal or cross-sectional studies assessing both peripheral artery disease (PAD), defined by a low ABI, and cognitive function. RESULTS: 12 publications were included in this review, of whom 6 reported cross-sectional analysis and 6 reported longitudinal analysis. All except one reported a significant association between a low ankle-brachial index and cognitive impairment, dementia or AD. Beyond cognitive impairment, patients with PAD are at an increased risk to develop dementia or Alzheimer's disease. CONCLUSION: In this review, we confirm that a low (<0.90) ABI can be considered as a marker of cognitive impairment and dementia. ABI provides independent and supplemental information on subject's susceptibility to develop cognitive disorders, along its usefulness to predict cardiovascular diseases (CVD). Given its availability, easiness, safety to patients and low cost, the ABI could be useful in clinical practice and research in the field of cognitive diseases.
OBJECTIVE: To investigate the association between a low ankle-brachial index (ABI) and several grades of cognitive disorders: cognitive impairment, dementia and Alzheimer's disease (AD), in the general population. METHODS: We performed a systematic review of the literature, including all prospective, longitudinal or cross-sectional studies assessing both peripheral artery disease (PAD), defined by a low ABI, and cognitive function. RESULTS: 12 publications were included in this review, of whom 6 reported cross-sectional analysis and 6 reported longitudinal analysis. All except one reported a significant association between a low ankle-brachial index and cognitive impairment, dementia or AD. Beyond cognitive impairment, patients with PAD are at an increased risk to develop dementia or Alzheimer's disease. CONCLUSION: In this review, we confirm that a low (<0.90) ABI can be considered as a marker of cognitive impairment and dementia. ABI provides independent and supplemental information on subject's susceptibility to develop cognitive disorders, along its usefulness to predict cardiovascular diseases (CVD). Given its availability, easiness, safety to patients and low cost, the ABI could be useful in clinical practice and research in the field of cognitive diseases.
Authors: Mark A Espeland; Anne B Newman; Kaycee Sink; Thomas M Gill; Abby C King; Michael E Miller; Jack Guralnik; Jeff Katula; Timothy Church; Todd Manini; Kieran F Reid; Mary M McDermott Journal: J Am Med Dir Assoc Date: 2015-04-11 Impact factor: 4.669
Authors: Mark A Espeland; Kristen M Beavers; Bethany Barone Gibbs; Karen C Johnson; Timothy M Hughes; Laura D Baker; John Jakicic; Mary Korytkowski; Marsha Miller; George A Bray Journal: Int J Geriatr Psychiatry Date: 2014-12-26 Impact factor: 3.485
Authors: Andrew W Gardner; Polly S Montgomery; Ming Wang; Biyi Shen; Ana I Casanegra; Federico Silva-Palacios; Zoltan Ungvari; Andriy Yabluchanskiy; Anna Csiszar; Shari R Waldstein Journal: Geroscience Date: 2021-09-09 Impact factor: 7.713
Authors: Correne A DeCarlo; Stuart W S MacDonald; David Vergote; Jack Jhamandas; David Westaway; Roger A Dixon Journal: J Gerontol B Psychol Sci Soc Sci Date: 2015-09-11 Impact factor: 4.077
Authors: Emily Cedarbaum; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Adaora A Adimora; Marcas Bamman; Mardge Cohen; Margaret A Fischl; Kunihiro Matsushita; Igho Ofotokun; Michael Plankey; Eric C Seaberg; Michael T Yin; Carl Grunfeld; Shant Vartanian; Anjali Sharma; Phyllis C Tien Journal: AIDS Date: 2019-11-01 Impact factor: 4.632